1Moreland LW,O'Dell JR,Paulus H,et al. A randomized comparativeeffectiveness study of oral triple therapy versus etanercept plus meth-otrexate in early,aggressive rheumatoid arthritis [ J]. ArthritisRheum,2012,64(9) :2824 -2835.
2Klarenbeek NB,Giiler-Yuksel M,van der Heijde DM,et al. A com-parison between the simplified erosion and narrowing score and theSharp-van der Heijde score : post hoc analysis from the Best study[J]. Ann Hheum Dis,2011 ,70(4) :714 -716. .
3Furst DE, Gayiis N, Bray V. Open-label, pilot protocol of patientswith rheumatoid arthritis who switch to infliximab after an incom-plete response to etanercept: the opposite study [ J] . Ann RheumDis,2007,66(7) :893 -899.
4Scallon B,Cai A,Solowski N,et al. Binding and functional compari-sons of two types of tumor necrosis factor antagonists[J]. J Pharma-col Exp Ther,2002,301 (2) :418 -426.
同被引文献14
1Kotak S, Mardekian J, Horowicz-Mehler N, et al. Impact of etaner- cept therapy on disease activity and health-related quality of life in moderate rheumatoid arthritis patients population from a national biti- sh oservational cohort[J]. Value Health, 2015,18(6) :817-823.
2Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenici- ty of TNF inhibitors : impact on clinical efficacy and tolerability in the management of autoimmune diseases, a systematic review and meta-a- nalysis[ J]. Bio Drugs,2015,29(4) :241-258.
3Obry A, Hardouin J, Lequerr6 T, et al. Identification of 7 proteins in sera of RA patients with potential to predict ETA/MTX treatment re- sponse [ J ]. Theranostics, 2015,5 ( 11 ) : 1214 -1224.
